Kathryn Haviland
Chief Executive Officer bij BLUEPRINT MEDICINES CORPORATION
Vermogen: 15 M $ op 31-03-2024
Profiel
Kathryn Haviland is lid van de raad van bestuur van Fulcrum Therapeutics, Inc. en Chief Operating Officer bij Blueprint Medicines Corp., lid van de Harvard Business School Health Industry Alumni Association en lid van de Biopharma Executive Council. Haviland was voorheen Vice President-Rare Diseases bij Idera Pharmaceuticals, Inc., Head-Commercial Development bij Sarepta Therapeutics, Inc. en Executive Director-Commercial Development bij PTC Therapeutics, Inc. Zij behaalde een bachelor aan de Wesleyan University en een MBA aan de Harvard Business School.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 07-03-2024 | 153 177 ( 0.25% ) | 15 M $ | 31-03-2024 | |
| 27-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Kathryn Haviland
| Bedrijven | Functie | Begin |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Chief Executive Officer | 04-04-2022 |
| FULCRUM THERAPEUTICS, INC. | Chairman | 10-01-2022 |
| Harvard Business School Health Industry Alumni Association | Corporate Officer/Principal | - |
Biopharma Executive Council
 Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Corporate Officer/Principal | - |
Bicara Therapeutics, Inc.
 Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Director/Board Member | 16-10-2023 |
Eerdere bekende functies van Kathryn Haviland
| Bedrijven | Functie | Einde |
|---|---|---|
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Corporate Officer/Principal | 01-12-2015 |
| SAREPTA THERAPEUTICS, INC. | Corporate Officer/Principal | 01-04-2014 |
| PTC THERAPEUTICS, INC. | Corporate Officer/Principal | 01-06-2012 |
Opleiding van Kathryn Haviland
| Wesleyan University | Undergraduate Degree |
| Harvard Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| SAREPTA THERAPEUTICS, INC. | Health Technology |
| PTC THERAPEUTICS, INC. | Health Technology |
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Idera Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which focuses on the clinical development, and commercialization of drug candidates for both oncology and rare disease indications. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Exton, PA. | Health Technology |
| Harvard Business School Health Industry Alumni Association | |
Biopharma Executive Council
Biopharma Executive Council Miscellaneous Commercial ServicesCommercial Services Biopharma Executive Council is a membership council that operates at the executive level in the biotech and pharmaceutical industries. The private company is based in Boston. | Commercial Services |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Bicara Therapeutics, Inc. is a company that develops first-in-class bifunctional antibodies for the treatment of solid tumors. The company is based in Cambridge, MA. The company's lead product candidate, bca101, is a first-in-class egfr/tgf-?-trap bifunctional antibody in clinical development for multiple tumor types. The company's bifunctional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Bicara has a deep pipeline of promising bifunctional antibodies and other biologics for treating solid tumors. The CEO of the company is Claire Mazumdar. | Health Technology |
